Benninger-Döring G, Boos J
Koordinierungszentrum für Klinische Studien, Universitätsklinikum Münster, 48129 Münster.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jul;49(7):675-80. doi: 10.1007/s00103-006-1288-6.
Non-commercial clinical trials may be of great benefit to the patients concerned. The 12th amendment to the German Drug Law (AMG) changed legal liability of the initiators of investigator-initiated clinical trials with extensive consequences for traditional project leaders. The central point under discussion is the sponsor's responsibility according to the AMG. Presently leading management divisions of university hospitals and universities are developing proceedings to assume sponsor responsibility by institutions (institutional sponsorship), which should enable investigator-initiated clinical trials to be conducted according to legal requirements in the future. Detailed problems and special questions can only be resolved in a single-minded fashion, and if necessary political processes should be catalyzed.
非商业性临床试验可能会给相关患者带来巨大益处。德国药品法(AMG)的第12次修订改变了研究者发起的临床试验发起者的法律责任,这对传统项目负责人产生了广泛影响。讨论的核心要点是AMG规定的申办者责任。目前,大学医院和大学的主要管理部门正在制定相关程序,以使机构承担申办者责任(机构申办),这有望在未来使研究者发起的临床试验能够依法开展。具体问题和特殊疑问只能通过一心一意的方式来解决,必要时还应推动政治进程。